Operating
Stock-Based Comp
United Therapeutics Stock-Based Comp decreased by 13.1% to $33.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $31.80M to $33.90M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows relatively stable performance with a 1.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.10M | $24.60M | $44.70M | -$21.10M | $65.50M | -$2.40M | $64.80M | -$12.40M | $13.80M | $21.10M | $16.60M | $25.60M | $49.70M | $41.70M | $27.00M | $31.80M | $37.80M | $39.10M | $39.00M | $33.90M |
| QoQ Change | — | -15.5% | +81.7% | -147.2% | +410.4% | -103.7% | >999% | -119.1% | +211.3% | +52.9% | -21.3% | +54.2% | +94.1% | -16.1% | -35.3% | +17.8% | +18.9% | +3.4% | -0.3% | -13.1% |
| YoY Change | — | — | — | — | +125.1% | -109.8% | +45.0% | +41.2% | -78.9% | +979.2% | -74.4% | +306.5% | +260.1% | +97.6% | +62.7% | +24.2% | -23.9% | -6.2% | +44.4% | +6.6% |
Range-$21.10M – $65.50M
CAGR+3.3%
Avg YoY Growth+106.2%
Median YoY Growth+42.8%
Current Streak2 quarters decline
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is United Therapeutics's stock-based comp?
- United Therapeutics (UTHR) reported stock-based comp of $33.90M in Q1 2026.
- How has United Therapeutics's stock-based comp changed year-over-year?
- United Therapeutics's stock-based comp increased by 6.6% year-over-year, from $31.80M to $33.90M.
- What is the long-term trend for United Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), United Therapeutics's stock-based comp has grown at a 1.6% compound annual growth rate (CAGR), from $138.50M to $147.70M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.